NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price & News

$26.25

+0.11 (+0.42%)

(As of 06/8/2023 ET)

Compare

Today's Range: $25.43
▼
$26.28
50-Day Range: $24.04
▼
$31.42
52-Week Range: $12.39
▼
$41.93

Volume: 483,423 shs
Average Volume: 937,676 shs
Market Capitalization: $1.76 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $50.17

Amylyx Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 91.1% Upside
$50.17 Price Target
Short Interest: Bearish
20.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.40
Based on 10 Articles This Week
Insider Trading: Selling Shares
$17.32 M Sold Last Quarter
Proj. Earnings Growth: 650.00%
From $0.42 to $3.15 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

72nd out of 986 stocks

Pharmaceutical Preparations Industry

28th out of 472 stocks

3.4

Analyst's Opinion

Consensus Rating
Amylyx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.17, Amylyx Pharmaceuticals has a forecasted upside of 91.1% from its current price of $26.25.
Amount of Analyst Coverage
Amylyx Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
20.13% of the float of Amylyx Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in Amylyx Pharmaceuticals has recently increased by 24.16%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Amylyx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Amylyx Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMLX.

3.0

News and Social Media Coverage

News Sentiment
Amylyx Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Amylyx Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
25 people have searched for AMLX on MarketBeat in the last 30 days. This is an increase of 79% compared to the previous 30 days.
MarketBeat Follows
6 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amylyx Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,324,496.00 in company stock.
Percentage Held by Insiders
12.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
70.55% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Amylyx Pharmaceuticals are expected to grow by 650.00% in the coming year, from $0.42 to $3.15 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amylyx Pharmaceuticals is -10.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amylyx Pharmaceuticals is -10.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Amylyx Pharmaceuticals has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Amylyx Pharmaceuticals has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Stock News Headlines

May 16, 2023 | marketbeat.com

Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch

Amylyx Pharmaceuticals is the rare young biotech that's profitable. The company earned $0.02 a share in Q1, and analysts expect profitability to grow.

June 6, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 9, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

June 3, 2023 | americanbankingnews.com

SVB Leerink Equities Analysts Boost Earnings Estimates for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

June 2, 2023 | americanbankingnews.com

Equities Analysts Offer Predictions for Amylyx Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:AMLX)

June 1, 2023 | reuters.com

Amylyx says European panel unlikely to endorse ALS drug

May 31, 2023 | msn.com

Amylyx Pharmaceuticals: Post Q1 Selloff Appears Overdone

May 30, 2023 | reuters.com

Amylyx says European drug regulator likely to reject ALS drug

June 9, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

May 30, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union

May 29, 2023 | americanbankingnews.com

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Large Growth in Short Interest

May 24, 2023 | americanbankingnews.com

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of "Moderate Buy" from Analysts

May 22, 2023 | markets.businessinsider.com

Mizuho Securities Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)

May 20, 2023 | americanbankingnews.com

Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $347,343.95 in Stock

May 18, 2023 | americanbankingnews.com

Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 6% Following Analyst Downgrade

May 17, 2023 | americanbankingnews.com

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) to Post FY2026 Earnings of $3.35 Per Share, HC Wainwright Forecasts

May 17, 2023 | americanbankingnews.com

Amylyx Pharmaceuticals, Inc. to Post Q4 2023 Earnings of $0.62 Per Share, SVB Leerink Forecasts (NASDAQ:AMLX)

May 16, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2023 Earnings Call Transcript

May 16, 2023 | msn.com

Mizuho Maintains Amylyx Pharmaceuticals (AMLX) Buy Recommendation

May 16, 2023 | finance.yahoo.com

New Forecasts: Here's What Analysts Think The Future Holds For Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

May 16, 2023 | americanbankingnews.com

Analyzing Amylyx Pharmaceuticals (AMLX) & Its Rivals

May 15, 2023 | americanbankingnews.com

Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Lowered to $50.00 at Mizuho

May 15, 2023 | seekingalpha.com

Amylyx: A Biotech Underdog's Resilient Performance And Promising Market Potential

May 14, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals, Inc. Just Reported A Surprise Profit, And Analysts Lifted Their Estimates

May 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Amylyx Pharmaceuticals Inc (AMLX) and Applied DNA Sciences (APDN)

May 12, 2023 | msn.com

Amylyx Up after Better-than-Expected Q1 Results

May 11, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results

See More Headlines

AMLX Price History

30 days | 90 days | 365 days | Advanced Chart

AMLX Company Calendar

Last Earnings: 3/13/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AMLX
CUSIP: N/A
CIK: 1658551
Web: amylyx.com
Phone: 617-682-0917
Fax: N/A
Employees: 296
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $50.17
High Stock Price Forecast: $54.00
Low Stock Price Forecast: $47.00
Forecasted Upside/Downside: +91.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 62.50
P/E Growth: 0.94
Net Income: $-198,380,000.00
Net Margins: N/A
Pretax Margin: -158.55%
Return on Equity: -57.84%
Return on Assets: -49.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.54
Quick Ratio: 7.28

Sales & Book Value

Annual Sales: $22.23 million
Price / Sales: 79.33
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.14 per share
Price / Book: 5.11

Miscellaneous

Outstanding Shares: 67,180,000
Free Float: 58,645,000
Market Cap: $1.76 billion
Optionable: Not Optionable
Beta: -0.86

Key Executives

Mr. Joshua B. Cohen (Age 31)
Co-Founder, Co-CEO & Director
Comp: $1M

Mr. Justin B. Klee (Age 32)
Co-Founder, Co-CEO & Director
Comp: $1M

Mr. James M. Frates M.B.A. (Age 56)
Chief Financial Officer
Comp: $695.12k

Ms. Gina M. Mazzariello (Age 52)
Chief Legal Officer & Gen. Counsel
Comp: $794.83k

Mr. Tom Holmes
Chief Technical Operations Officer

Ms. Shauna Horvath
Head of Global Marketing

Ms. Debra L. Canner (Age 64)
Global Head of HR & CHRO

Ms. Margaret M. Olinger M.B.A (Age 58)
Global Head of Commercial & Chief Commercial Officer

Dr. Patrick D. Yeramian M.D. (Age 64)
MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer

Mr. Chris Aiello
Head of Canada & GM

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMLX Stock - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMLX shares.
View AMLX analyst ratings or view top-rated stocks.
What is Amylyx Pharmaceuticals' stock price forecast for 2023?: 6 equities research analysts have issued 12 month target prices for Amylyx Pharmaceuticals' stock. Their AMLX share price forecasts range from $47.00 to $54.00. On average, they expect the company's stock price to reach $50.17 in the next year. This suggests a possible upside of 91.1% from the stock's current price.
View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts.
How have AMLX shares performed in 2023?: Amylyx Pharmaceuticals' stock was trading at $36.95 at the beginning of 2023. Since then, AMLX stock has decreased by 29.0% and is now trading at $26.25.
View the best growth stocks for 2023 here.
Are investors shorting Amylyx Pharmaceuticals?: Amylyx Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 8,530,000 shares, an increase of 24.2% from the April 30th total of 6,870,000 shares. Based on an average daily trading volume, of 948,300 shares, the days-to-cover ratio is currently 9.0 days. Approximately 20.1% of the shares of the stock are short sold.
View Amylyx Pharmaceuticals' Short Interest.
When is Amylyx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our AMLX earnings forecast.
How were Amylyx Pharmaceuticals' earnings last quarter?: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its earnings results on Monday, March, 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.12. The business had revenue of $21.89 million for the quarter, compared to analysts' expectations of $3.05 million.
What ETFs hold Amylyx Pharmaceuticals' stock?: ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Simplify Health Care ETF (PINK), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and Invesco DWA SmallCap Momentum ETF (DWAS).

When did Amylyx Pharmaceuticals IPO?: (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.
What is Amylyx Pharmaceuticals' stock symbol?: Amylyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLX."
Who are Amylyx Pharmaceuticals' major shareholders?: Amylyx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (8.99%), BlackRock Inc. (5.39%), Federated Hermes Inc. (2.75%), Pictet Asset Management SA (2.14%), State Street Corp (1.59%) and Emerald Advisers LLC (1.45%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian.
View institutional ownership trends.
How do I buy shares of Amylyx Pharmaceuticals?: Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Amylyx Pharmaceuticals' stock price today?: One share of AMLX stock can currently be purchased for approximately $26.25.
How much money does Amylyx Pharmaceuticals make?: Amylyx Pharmaceuticals (NASDAQ:AMLX) has a market capitalization of $1.76 billion and generates $22.23 million in revenue each year. The company earns $-198,380,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.
How many employees does Amylyx Pharmaceuticals have?: The company employs 296 workers across the globe.
How can I contact Amylyx Pharmaceuticals?: The official website for the company is amylyx.com. The company can be reached via phone at 617-682-0917 or via email at investors@amylyx.com.

This page (NASDAQ:AMLX) was last updated on 6/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial